AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AAPG · NASDAQ · Biotechnology

Ascentage Pharma (ADR)

Develops and commercializes hematology therapies in China and global clinical trials.

$17.98

After-hours close−0.02 (−0.08%)

At close$18.00(−3.92%)

Something off on this page? Send us feedback.

Profile

Ascentage Pharma Group InternationalAAPGHealth Care

Develops and commercializes small-molecule therapies for hematologic malignancies. China-approved olverembatinib and lisaftoclax form its commercial base, while global Phase III programs seek additional uses; no named product or pipeline program is approved by the U.S. FDA.

Discovers, develops and commercializes small-molecule therapies for hematologic malignancies. Its drug-discovery work targets apoptosis pathways and kinase mutations; China-approved olverembatinib treats CML, while lisaftoclax is approved for specified previously treated adult CLL/SLL patients.

Commercial activity is centered in China, alongside global Phase III programs investigating expanded uses for both products across CML, Ph+ ALL, CLL/SLL, AML, higher-risk MDS and SDH-deficient GIST. The platforms encompass Bcl-2, MDM2-p53 and kinase-mutation targets.

Chinese approvals underpin the commercial base, while the named products and pipeline programs have not been approved by the U.S. FDA.

Company facts

CEODajun Yang

ListedJan 24, 2025

ExchangeNASDAQ

HeadquartersRockville, MD

CountryChina

Employees800

CIK0002023311

ISINUS04390B1052

Key statistics

Market cap$1.70B

EPS (ttm)−$2.31

P/E (ttm)−7.92

ROE-153.8%

P/B20.59

P/S18.04

Dividend yield—

Beta1.22vs XLV −0.00

Year to date −31.8% · Average volume (30d) 5.6K

Analysts

No analyst consensus on record.

Earnings

EPS

Estimate$0.02

Reported−$1.28−7,840.4%

Revenue

Estimate$24.1M

Reported$44.0M+83.1%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 19, 2026Q2 FY26	$0.02	−$1.28	−7,840.4%	$24.1M	$44.0M	+83.1%	−0.93%
Aug 18, 2026Q2 FY26	−$0.22	−$1.30	−491.0%	$53.6M	$44.9M	−16.4%	0.00%
Mar 24, 2026Q4 FY25	−$0.83	−$0.65	+21.7%	$44.4M	$49.5M	+11.5%	+0.27%
Aug 20, 2025Q2 FY25	—	−$0.96	—	—	$32.6M	—	+1.06%

View details

Financial highlights

	Q4 FY23	Q2 FY24	Q4 FY24	Q2 FY25	Q4 FY25	Q2 FY26
Revenue	$11.8M	$122.6M	$23.3M	$34.8M	$49.7M	$44.5M
Gross profit	$10.0M	$120.3M	$21.3M	$31.6M	$39.5M	$37.3M
Operating income	−$79.2M	$28.0M	−$84.3M	−$82.4M	−$95.4M	−$110.7M
Net income	−$77.9M	$24.3M	−$84.6M	−$87.9M	−$95.2M	−$120.2M
Diluted EPS	−$1.07	$0.33	−$1.08	−$1.03	−$1.03	−$1.29
Gross margin	84.4%	98.2%	91.1%	90.7%	79.4%	83.9%
Operating margin	-671.1%	22.8%	-361.2%	-237.1%	-191.8%	-248.9%

Balance sheet, Jun 30, 2026Cash & short-term investments $282.1M · Total debt $311.8M · Total assets $482.4M · Shareholders' equity $82.8M

Dividends

No dividends on record.

Ownership

Institutions 0.03%Insiders —

Shares outstanding — · Float —

Shares outstanding and float — provider count disagrees with the price.

Insiders — filings are in the shares behind the receipt.

The provider's share count does not square with the market price, so neither it nor anything divided by it is shown.

This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.

The institutional figure is the one the filers report, not a quotient recomputed on the share count.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	Form	Filed
Point72 Asset Management, L.P.	16.1K	13F	May 15, 2026
XY Capital Ltd	13.0K	13F	May 12, 2026
Tower Research Capital LLC (TRC)	518	13F	May 15, 2026
Morgan Stanley	498	13F	May 15, 2026
UBS Group AG	124	13F	May 5, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.